

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 14, 2025

PE/Cyanine7 anti-mouse TNF-?

RRID:AB_2256076

Type: Antibody

Proper Citation

(BioLegend Cat# 506324, RRID:AB_2256076)

Antibody Information

URL: http://antibodyregistry.org/AB_2256076

Proper Citation: (BioLegend Cat# 506324, RRID:AB_2256076)

Target Antigen: TNF-alpha

Host Organism: rat

Clonality: monoclonal

Comments: Applications: ICFC

Antibody Name: PE/Cyanine7 anti-mouse TNF-?

Description: This monoclonal targets TNF-alpha

Target Organism: mouse

Clone ID: Clone MP6-XT22

Antibody ID: AB_2256076

Vendor: BioLegend

Catalog Number: 506324

Alternative Catalog Numbers: 506323

Record Creation Time: 20241016T221020+0000

Record Last Update: 20241016T221958+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-mouse TNF-?.

No alerts have been found for PE/Cyanine7 anti-mouse TNF-?.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Ran L, et al. (2024) The transcription regulator ID3 maintains tumor-specific memory CD8+ T cells in draining lymph nodes during tumorigenesis. Cell reports, 43(9), 114690.

Mei Y, et al. (2024) IL-37 dampens immunosuppressive functions of MDSCs via metabolic reprogramming in the tumor microenvironment. Cell reports, 43(3), 113835.

Case JB, et al. (2024) A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice. Cell host & microbe, 32(12), 2131.

Brook B, et al. (2024) The BNT162b2 mRNA vaccine demonstrates reduced age-associated TH1 support in vitro and in vivo. iScience, 27(11), 111055.

Oami T, et al. (2024) Claudin-2 upregulation enhances intestinal permeability, immune activation, dysbiosis, and mortality in sepsis. Proceedings of the National Academy of Sciences of the United States of America, 121(10), e2217877121.

Tooley K, et al. (2024) Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity. Cell reports. Medicine, 5(7), 101640.

McDonald B, et al. (2023) Canonical BAF complex activity shapes the enhancer landscape that licenses CD8+ T cell effector and memory fates. Immunity, 56(6), 1303.

Guo M, et al. (2023) Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control. Cell reports, 42(9), 113047.

Camargo CP, et al. (2023) Adhesion analysis via a tumor vasculature-like microfluidic device identifies CD8+ T cells with enhanced tumor homing to improve cell therapy. Cell reports, 42(3), 112175.

Virassamy B, et al. (2023) Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. *Cancer cell*, 41(3), 585.

West EE, et al. (2023) Loss of CD4+ T cell-intrinsic arginase 1 accelerates Th1 response kinetics and reduces lung pathology during influenza infection. *Immunity*, 56(9), 2036.

Hope JL, et al. (2023) PSGL-1 attenuates early TCR signaling to suppress CD8+ T cell progenitor differentiation and elicit terminal CD8+ T cell exhaustion. *Cell reports*, 42(5), 112436.

Qu L, et al. (2022) Circular RNA vaccines against SARS-CoV-2 and emerging variants. *Cell*, 185(10), 1728.

Dähling S, et al. (2022) Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches. *Immunity*, 55(4), 656.

Li Y, et al. (2022) Sexual dimorphism in neurological function after SCI is associated with disrupted neuroinflammation in both injured spinal cord and brain. *Brain, behavior, and immunity*, 101, 1.

Ertuna YI, et al. (2021) Vectored antibody gene delivery restores host B and T cell control of persistent viral infection. *Cell reports*, 37(9), 110061.

Acharya N, et al. (2020) Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment. *Immunity*, 53(3), 658.

Kumar R, et al. (2020) Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. *Cell reports*, 30(8), 2512.

Dai L, et al. (2020) A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. *Cell*, 182(3), 722.

Kurtulus S, et al. (2019) Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells. *Immunity*, 50(1), 181.